The nomination of Markus Lusser as President was announced by Abcam today. Markus, an experienced Danaher executive, joins Abcam at a critical juncture when the business merges into the Danaher Life Sciences division. His broad range of commercial and digital experience in the life sciences and medical device sectors will support Abcam’s continued growth as it provides cutting-edge solutions that satisfy client demands and advance the sector.
After joining Danaher in 2011, Markus most recently held the positions of Vice President and Chief Customer Officer for the Life Sciences Innovations Group. In this role, he assisted in developing and implementing Danaher’s cross-OpCo strategy, which aims to increase the company’s market share and growth in the biologics sector. He had previously served as President of Leica Microsystems (LMS), where he successfully led associate engagement, commercial execution, and innovation to produce increased cash flow, accelerated organic growth, and improved profitability. He oversaw the successful digital transformation initiatives of LMS, which included ground-breaking inventions like ARveo—the first surgical imaging platform in the world to deliver augmented reality for brain surgery. Markus spent twenty years with Siemens Healthineers and was in charge of sizable international commercial organizations before joining Danaher. Markus graduated at HTBLA in Innsbruck, Austria, with a degree in engineering in electronics.
Markus is a seasoned people manager who is enthusiastic about advancing the knowledge and expertise of his interdisciplinary teams. In order to maximize a company’s combined knowledge and assets and generate value for stakeholders and customers, his leadership approach cultivates customer-centric cultures.
Markus expressed his excitement over the appointment, saying that he was looking forward to working with Abcam’s brilliant and diverse teams to tackle challenging problems and accelerate our clients’ success. As President of Abcam, my goal is to keep fostering an environment where the client is at the center of everything we do. This culture is based on the caliber of our products, strong partnerships, and an emphasis on industry innovation.
Alan Hirzel, who led Abcam as CEO since 2014, is replaced by Markus.
With nine sites and operations in more than 130 countries, Abcam has a significant global footprint. Its headquarters have been in Cambridge, UK, since 1998. Around 1,750 colleagues work for it, and it supports 750,000 researchers globally.
At Abcam, we think that collaboration makes the scientific community advance more quickly and thoroughly. Additionally, we must collaborate in novel ways if we are to continue producing groundbreaking discoveries. We therefore continuously innovate to support scientists in advancing their research by offering goods and services that are critical to basic science, drug development, and therapeutic and diagnostic applications. Our first goal was to give life scientists all across the world the best biological reagents available. In order to accelerate scientific progress in fields including cancer, neurological illnesses, infectious diseases, and metabolic disorders, we currently support 750,000 researchers across more than 130 countries.
